Study of NVN1000 Topical Gel and Topical Gel Vehicle in the Treatment of Moderate to Severe Acne Vulgaris

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to compare the tolerability, safety and efficacy of NVN1000 Topical Gel and Topical Gel Vehicle in the treatment of subjects with moderate to severe acne vulgaris.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novan, Inc.
• Treatments: Nitric Oxide

Criteria

Inclusion Criteria:

• Baseline IGA score of moderate (3) or severe (4)

• Minimum of 20 but no more than 40 facial inflammatory lesions

• Minimum of 20 but not more than 60 facial non-inflammatory lesions

• No more than 2 facial nodules

Exclusion Criteria:

• Dermatological conditions on the face that could interfere with clinical evaluations

• Underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive

• History of experiencing significant burning or stinging when applying any facial treatment

• Female subjects, if they are pregnant,nursing mothers, or planning to become pregnant during the study

• Have used estrogens or oral contraceptives for less than 90 days immediately preceding the Baseline visit, discontinued use of estrogens or oral contraceptives less than 90 days prior to Baseline,or planning to begin or discontinue use of this therapy during the treatment period

• Have used medications and/or vitamins which are reported to exacerbate acne during the 180 days immediately preceding the Baseline visit

• Use concomitantly over-the-counter (OTC) products that contain ingredients such as benzoyl peroxide,salicylic acid,alpha-hydroxy acid,retinol or glycolic acids

• Have not undergone the specified washouts for topical preparations,systemic medications and procedures noted in the protocol